VOR · Vor Biopharma Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $17.59M | - | $14.14M | $261.50M | $26.70M | - | $21.82M | $21.82M | $24.32M | - |
| SG&A | $17.57M | - | $13.96M | $12.79M | $6.59M | - | $6.70M | $7.21M | $8.00M | - |
| Total Operating Expenses | $35.16M | - | $28.11M | $274.28M | $33.29M | - | $28.51M | $29.04M | $32.33M | - |
| D&A | $28.0K | - | - | $2.10M | $825.0K | - | $900.0K | $900.0K | $943.0K | - |
| Operating Income | ($35.16M) | - | ($28.11M) | ($274.28M) | ($33.29M) | - | ($28.51M) | ($29.04M) | ($32.33M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($219.59M) | - | ($812.68M) | ($1.57B) | ($32.49M) | - | ($27.56M) | ($27.84M) | ($30.80M) | - |
| EPS - Basic | ($5.11) | - | ($121.63) | ($251.20) | ($5.20) | - | ($8.00) | ($8.20) | ($9.00) | - |
| EPS - Diluted | ($5.11) | - | ($121.63) | ($251.20) | ($5.20) | - | ($8.00) | ($8.20) | ($9.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $169.87M | $396.49M | $160.46M | $190.57M | $50.05M | $81.95M | $52.80M | $76.08M | $44.96M | $31.36M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.04M | $5.13M | $885.0K | $669.0K | $3.73M | $1.50M | $1.32M | $2.01M | $2.33M | $815.0K |
| Current Assets | $500.78M | $458.11M | $172.49M | $204.93M | $64.85M | $96.51M | $67.30M | $90.26M | $111.82M | $140.80M |
| Total Assets | $506.75M | $464.13M | $176.24M | $205.37M | $109.31M | $142.89M | $115.99M | $141.59M | $167.03M | $198.13M |
| Current Liabilities | $16.08M | $25.17M | $18.84M | $58.77M | $16.73M | $18.61M | $14.35M | $13.80M | $13.21M | $15.57M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $657.17M | $628.44M | $2.40B | $1.71B | $43.24M | $46.23M | $43.04M | $43.51M | $43.99M | $47.40M |
| Stockholders' Equity | ($150.42M) | ($164.31M) | ($2.23B) | ($1.51B) | $66.07M | $96.66M | $72.95M | $98.08M | $123.03M | $150.72M |
| Retained Earnings | ($1.37B) | ($1.15B) | ($2.88B) | ($2.06B) | ($489.48M) | ($456.99M) | ($426.28M) | ($398.72M) | ($370.88M) | ($340.08M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($38.25M) | - | - | - | ($31.07M) | - | - | - | ($30.46M) | - |
| Investing Cash Flow | ($263.24M) | - | - | - | ($230.0K) | - | - | - | $43.97M | - |
| Financing Cash Flow | $74.87M | - | - | - | ($606.0K) | - | - | - | $96.0K | - |
| CapEx | $48.0K | - | - | - | $231.0K | - | - | - | $114.0K | - |
| Free Cash Flow | ($38.29M) | - | - | - | ($31.30M) | - | - | - | ($30.58M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.17 | - | - | - | 0.96 | - | - | - | 0.99 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -43.3% | - | -461.1% | -766.3% | -29.7% | - | -23.8% | -19.7% | -18.4% | - |
| Return on equity | 146.0% | - | 36.5% | 104.5% | -49.2% | - | -37.8% | -28.4% | -25.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 31.15 | 18.20 | 9.16 | 3.49 | 3.88 | 5.19 | 4.69 | 6.54 | 8.46 | 9.04 |
| Quick ratio | 31.15 | 18.20 | 9.16 | 3.49 | 3.88 | 5.19 | 4.69 | 6.54 | 8.46 | 9.04 |
| Cash ratio | 10.57 | 15.75 | 8.52 | 3.24 | 2.99 | 4.40 | 3.68 | 5.51 | 3.40 | 2.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -3.37 | -2.82 | -0.08 | -0.14 | 1.65 | 1.48 | 1.59 | 1.44 | 1.36 | 1.31 |
| Liabilities / Assets | 1.30 | 1.35 | 13.63 | 8.33 | 0.40 | 0.32 | 0.37 | 0.31 | 0.26 | 0.24 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | 27.1x | - | 13.1x | 13.9x | 26.2x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -5.6% | - | 1.4% | -844.7% | -3.0% | - | 19.3% | 9.8% | -6.3% | - |
| Net income growth (YoY) | -575.9% | - | -2848.9% | -5552.7% | -5.5% | - | 17.0% | 7.1% | -8.3% | - |
| EPS growth (YoY) | 1.7% | - | -1420.4% | -2963.4% | 42.2% | - | -1532.7% | -1722.2% | -1993.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -22.4% | - | - | - | -2.3% | - | - | - | -25.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | -46.3% | -35.9% | -58.3% | -52.0% | -46.6% | -39.9% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Vor Biopharma Inc. against the 5 most active filers in the same SIC group.